Baxter International Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on October 25, 2017, reports the issuance of an earnings press release for the quarterly period ended September 30, 2017. The filing serves to disclose the Company's results of operations and financial condition for the third quarter of 2017.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it defines the non-GAAP financial measures included in the attached press release (Exhibit 99.1), which include:
- Adjusted income from continuing operations
- Adjusted diluted earnings per share from continuing operations
- Adjusted operating margin from continuing operations
- Constant currency sales
- Operational sales
- Free cash flow (defined as operating cash flow less capital expenditures)
These measures exclude special items, which the Company defines as highly variable, difficult to predict, or unusual events that may substantially impact reported operations.
Material Changes and Methodology
The filing details specific adjustments made to calculate non-GAAP metrics to facilitate period-over-period analysis:
- Constant Currency Sales: Adjusts net sales assuming foreign currency exchange rates remained unchanged between periods.
- Operational Sales: Excludes the impact of foreign exchange, generic competition for U.S. cyclophosphamide, the Claris Injectables acquisition, and select strategic product exits.
- Special Items: Intangible asset amortization is excluded to align with internal management performance assessments.
The filing does not contain specific data on material changes versus the prior comparable period; such data is contained within the referenced press release.
Guidance, Outlook, and Risks
Management utilizes these non-GAAP measures for financial planning, monitoring business unit performance, and determining incentive compensation. The filing includes a caution that future events or new information may result in actual results differing from current estimates. Investors are advised that non-GAAP measures may differ from similar measures used by other companies and should not be viewed as substitutes for GAAP financial information.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 25, 2017) for specific numerical results.
- Verify the reconciliation of non-GAAP measures to the most directly comparable GAAP financial measures.
- Assess the specific impact of the Claris Injectables acquisition and U.S. cyclophosphamide competition on operational sales.
- Confirm the definition of "special items" excluded from adjusted earnings for this period.
- Examine the consolidated financial statements in the Company's 10-Q for the period ended September 30, 2017, for GAAP-compliant data.